Related Experiment Video
Updated: Feb 15, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
P21 activated kinase signaling in cancer
Chetan K Rane1, Audrey Minden1
1Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854, United States.
Abstract:
The p21 Activated Kinases (PAKs) are a family of serine threonine kinases, that consist of 6 members, PAKs 1-6, which are positioned at an intersection of multiple signaling pathways implicated in oncogenesis. The PAKs were originally identified as protein kinases that function downstream of the Ras related Rho GTPases Cdc42 and Rac. PAK1 and PAK4, which belong to Group I and Group II PAKs, respectively, are most often associated with tumorigenesis. On account of their well characterized roles in cancer, several small molecule inhibitors are being developed to inhibit the PAKs, and there is interest in investigating their efficacy as either first line or adjuvant treatments for cancer. Studies to delineate PAK regulated signaling pathways as well as the long term effects of PAK overexpression on gene expression are beginning to shed light on the mechanism by which PAK proteins may lead to cancer when they are overexpressed or activated. This review will describe the association between PAK expression in cancer, with a focus on PAK1 and PAK4, which are most often associated with the disease. The current understanding of the molecular mechanisms by which the PAKs operate in cancer will be discussed. We will also review some of the potential drug candidates, and discuss which of them are currently being tested for their efficacy in cancer treatments.
Insights
p21 Activated Kinases (PAKs) are key signaling proteins in cancer. Inhibitors targeting PAK1 and PAK4 show promise as potential cancer treatments, with ongoing clinical investigations.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- p21 Activated Kinases (PAKs) are serine/threonine kinases involved in multiple signaling pathways.
- PAKs function downstream of Rho GTPases Cdc42 and Rac.
- PAKs 1-6 are implicated in oncogenesis, with PAK1 and PAK4 frequently associated with tumorigenesis.
Purpose of the Study:
- To review the association between PAK expression and cancer.
- To discuss the molecular mechanisms of PAKs in cancer.
- To review PAK-targeting drug candidates and their clinical efficacy.
Main Methods:
- Literature review of PAKs in cancer.
- Analysis of signaling pathways regulated by PAKs.
- Examination of small molecule inhibitors targeting PAKs.
Main Results:
- PAK1 and PAK4 are significantly associated with various cancers.
- Understanding of PAK-mediated oncogenic signaling is advancing.
- Several PAK inhibitors are under development and clinical testing for cancer therapy.
Conclusions:
- PAKs, particularly PAK1 and PAK4, play crucial roles in cancer development.
- Targeting PAK signaling represents a promising therapeutic strategy for cancer.
- Further research into PAK inhibitors is warranted for cancer treatment.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Endocrine Signaling
Yeast Signaling
Intracellular Signaling Cascades

